A new study investigates how ketamine infusion affects different parts of the brain and could be an effective pharmaceutical ...

Last month, Johnson & Johnson’s esketamine nasal spray Spravato secured the first FDA approval as a monotherapy for treatment-resistant depression (TRD). Although the drug, a derivative of ketamine, ...

The Food and Drug Administration has approved a new nasal spray for the treatment of severe depression. On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine ...

Esketamine, a derivative of ketamine, is a rapid-acting antidepressant. Previously, it was approved in combination with oral antidepressants for individuals with treatment-resistant depression.

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...

Meeting Coverage > Psych Congress Esketamine Also Effective Without Adjunctive Antidepressant — Trial data may expand use, with "opportunity to truly individualize treatment" by Kristen Monaco ...

A single low dose of esketamine after childbirth reduces depressive episodes at 42 days postpartum among mothers with prenatal depression, according to a study published online April 10 in The BMJ.

Esketamine-treated women had lower EPDS scores on day 7 and day 42 (median difference, -3). Individuals receiving esketamine also had reduced HDRS scores 42 days after delivery (mean difference, -4).

A single low dose injection of esketamine given immediately after childbirth reduces major depressive episodes in individuals with depressive symptoms during pregnancy (prenatal depression), finds ...

Esketamine administered intravenously during elective cesarean delivery may significantly reduce depressive symptoms in the early postpartum period, according to study results published in JAMA ...

Unlike ketamine, esketamine is administered only in a physician's office with a strict treatment protocol enforced by a mandatory Risk Evaluation and Mitigation Strategy program. By contrast ...